CMV Retinitis Trial: Your Own Cells vs. Resistant Virus
Part of Blood & lymphatic, Cancer, Eyes & vision, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment made from your own immune cells (called LB-DTK-CMV) for a type of CMV eye infection that is not getting better with standard antiviral drugs. The goal is to see if these cells can safely control the infection and improve your vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You had a stem cell or organ transplant, or received strong immune-suppressing treatment for an autoimmune disease.
- Your CMV eye infection (retinitis) is not responding to standard antiviral therapy, or you have a drug-resistant strain.
- You are not pregnant, or if you could become pregnant, you are using effective birth control.
- You have not received certain T-cell-suppressing drugs in the past 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This trial tests a treatment using specially grown immune cells (virus-specific lymphocytes) to fight a stubborn CMV infection that hasn't gotten better with usual medicines. It is for people who have had a stem cell transplant and need help controlling CMV.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Hear when a new CMV Retinitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.